ALX has a Chinese challenger
HanchorBio’s HCB301 is among the latest industry projects beginning first-in-human trials.
Lilly points in a new radiopharma direction
After being burned by Point, Lilly is taking a slower approach with Radionetics.
Sutro reads the farletuzumab tea leaves
Farletuzumab ecteribulin follows its parent MAb with a setback, spelling possible bad news for Sutro.
FDA green and red lights: June 2024
Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.
Merck’s big ADC deal takes a blow
A complete response letter for Merck & Co and Daiichi’s patritumab deruxtecan might not be fatal, but it’s certainly embarrassing.
Bristol overtakes Amgen in colorectal
Meanwhile, Bristol’s other competition in this disease looks set to come from China.
Toxicity hits BioNTech’s MediLink tie-up
A mysterious ASCO poster, patient deaths and now clinical hold; where next for BioNTech’s ADC deal?
FDA green and red lights: May 2024
Breyanzi and Imdelltra head up May’s approvals, while camrelizumab’s CRL is a lowlight.
